YOYabo OuYang

Yabo OuYang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yabo OuYang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Dexi Chen

    Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Feili Wei

    Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Haiying Jin

    Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China

    1 shared publication
  • Hu Xin Tao

    State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China; Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States

    1 shared publication
  • Jianping Sun

    Biomedical Information Center, Bejing Youan Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Kunxue Hong

    State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Laboratory validation of an RNA/DNA hybrid tagmentation based mNGS workflow on SARS-CoV-2 and other respiratory RNA viruses detection

    by Feili Wei, Yanhua Yu, Zhongjie Hu, Rui Wang, Xianghua Guo, Haiying Jin, Shan Guo, Yabo Ouyang, Ying Shi, Ronghua Jin, et al.

    Background: Acute respiratory infection caused by RNA viruses is still one of the main diseases all over the world such as SARS CoV 2 and Influenza A virus. mNGS was a powerful tool for ethological diagnosis. But there were some challenges during mNGS implementation in clinical settings such as time consuming manipulation and lack of comprehensive analytical validation. Methods: We set up CATCH that was a mNGS method based on RNA and DNA hybrid tagmentation via Tn5 transposon. Seven respiratory RNA viruses and three subtypes of Influenza A virus had been used to test capabilities of CATCH on detection and quantification. Analytical performance of SARS CoV 2 and Influenza A virus had been determined with reference standards. We compared accuracy of CATCH with quantitative real time PCR by using clinical 98 samples from 64 COVID19 patients. Results: We minimized the library preparation process to 3 hours and handling time to 35 minutes. Duplicate filtered RPM of 7 respiratory viruses and 3 Influenza A virus subtypes were highly correlated with viral concentration. LOD of SARS CoV 2 was 39.2 copies/test and of Influenza A virus was 278.1 copies/mL. Comparing with quantitative real time PCR, the overall accuracy of CATCH was 91.4%. Sensitivity was 84.5% and specificity was 100%. Meanwhile, there were significant difference of microbial profile in oropharyngeal swabs among critical, moderate patients and healthy controls. Conclusion: Although further optimization is needed before CATCH can be rolled out as a routine diagnostic test, we highlight the potential impact of it advancing molecular diagnostics for respiratory pathogens.


  • Open Access

    Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China

    by Yabo OuYang, Jianping Sun, Yang Huang, Lu Lu, Weisi Xu, Xintao Hu, Kunxue Hong, Shibo Jiang, Yiming Shao, Liying Ma

    Background: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous and heterologous plasmas has not been well studied. Results: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intra- and inter-subtype neutralization sensitivity to the neutralization antibodies in the plasmas from patients infected by HIV-1 B’ and CRF07_BC subtypes, respectively. We found that the plasmas from the HIV-1 B’-infected patients could potently neutralize heterologous viruses of subtype B’ with mean ID50 titer (1/x) of about 67, but they were not effective in neutralizing autologous viruses of subtype B’ with mean ID50 titer (1/x) of about 8. The plasmas from HIV-1 CRF07_BC-infected patients exhibited weak inter-subtype neutralization activity against subtype B’ viruses with ID50 titer (1/x) is about 22. The neutralization sensitivity of HIV-1 B’ isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B’-infected patients (Spearman’s r = −0.657, P = 0.020), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman’s r = −0.493, P = 0.034), but positively correlated with the viral load (Spearman’s r = 0.629, P = 0.028). It had no correlation with the length of V1-V5 regions or the CD4+ T cell count. Virus AH259V has low intra-subtype neutralization sensitivity, it can be neutralized by 17b (IC50: 10μg/ml) and 447-52D (IC50: 1.6μg/ml), and the neutralizing antibodies (nAbs) in plasma AH259P are effective in neutralizing infection by the primary HIV-1 isolates with different subtypes with ID50 titers (1/x) in the range of 32–396. Conclusions: These findings suggest that the HIV-1 subtype B’ viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120. Some of primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody responses.